drugset
drugset / Trial / NCT04080297

Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen

NCT04080297 ↗

Phase 1 Completed 21 enrolled Que Oncology
Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.

Timeline

Start
2014-01-10
Primary completion
2014-07-28
Completion
2014-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Q-122 Unknown 100 mg Oral
Subject Q-122 Unknown 200 mg Oral

Indications

No indication recorded.